PHILOGEN S.p.A.

Pharmaceutical, biopharmaceutical, and veterinary preparations for the treatment of cancer, particularly skin cancer, including melanoma and non-melanoma skin cancer; antibodies and antibody fragments derivatives including human monoclonal antibodies and related fragments conjugated to cytokines.

Biopharmaceutical preparations for the treatment of cancers; antibodies and antibody derivatives and fragments, namely, human monoclonal antibodies and their derivatives and fragments for medical use; biopharmaceutical preparations for the treatment of cancer of the skin, of the brain, and of soft tissue

Biopharmaceutical preparations for the treatment of cancers; antibodies and antibody derivatives and fragments, namely, human monoclonal antibodies and their derivatives and fragments for medical use; biopharmaceutical preparations for the treatment of cancer of the brain and of soft tissue

Biopharmaceutical preparations for the treatment of cancers; antibodies and antibody derivatives and fragments, namely, human monoclonal antibodies and their derivatives and fragments for medical use; biopharmaceutical preparations for the treatment of cancer of the brain and of soft tissue

Biopharmaceutical preparations for the treatment of cancers; antibodies and antibody derivatives and fragments, namely, human monoclonal antibodies and their derivatives and fragments for the treatment of cancer; biopharmaceutical preparations for the treatment of cancer of the skin